It was a pleasant surprise to see not one, but two recent commentaries on the subject of biosimilars in prestigious publications such as the New England Journal of Medicine (NEJM) and the Journal of Clinical Oncology (JCO).
“First, do no harm,” the Hippocratic Oath says. In today’s environmentally complex world, that becomes more of a challenge because people and the planet may unintentionally be harmed by the very products and processes meant to heal.
Lowering costs in the health care supply chain begins at the negotiating table. Multiple vendors are considered and clinicians are often deeply involved in product selection. The volume commitment is factored in, and the price is set.
Three decades ago, health care was largely a service industry, structured around individual physician practices: doctors treated patients, hospitals provided supporting resources, and insurers or the government (through Medicare and Medicaid) paid costs plus a small margin.
In addition to caring for critically ill patients, caregivers and support staff are battling changes to workload, shortages in necessary PPE and concern for the safety of their own families; all leaving them vulnerable to extreme stress.
This area is reserved for members of the news media. If you qualify, please update your user profile and check the box marked "Check here to register as an accredited member of the news media". Please include any notes in the "Supporting information for media credentials" box. We will notify you of your status via e-mail in one business day.